Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galecto Inc.
The listings of two vaccine manufacturers and fundraisings by seven other biopharma ventures generate around $1.2bn in new financing for Chinese companies focusing on a broad variety of therapeutic areas and indicating continued investor interest.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
Former Novartis CEO Jimenez co-founded Aditum with former NIBR president Mark Fishman; they raised $133m and are launching Tempero Bio. Also, Atea, Galecto and SQZ went public along with one more health care SPAC, Royalty Pharma upped its Vertex royalty revenues and Mirati’s FOPO raised $926.3m.
- Drug Delivery
- Other Names / Subsidiaries
- PharmAkea, Inc.
- Galecto Biotech Inc.